注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Genprex Inc是一家临床阶段的基因治疗公司。该公司专注于开发癌症和糖尿病的治疗方法。该公司的主要癌症候选药物REQORSA免疫原治疗药物(也称为GPX-001)被开发用于治疗非小细胞肺癌(NSCLC)和小细胞肺癌(SCLC)。REQORSA中的活性剂是一种TUSC2基因表达质粒,被封装在DOTAP胆固醇纳米颗粒中。TUSC2是一种多功能基因,有助于抑制癌症和促进正常细胞调节。该公司利用其ONCOPREX纳米颗粒递送系统将TUSC2基因表达质粒递送至癌细胞。该公司的糖尿病基因疗法,也称为GPX-002,旨在通过将胰腺中的α细胞转化为功能性β样细胞来发挥作用,这些细胞可以产生胰岛素,但与β细胞不同,可以避开人体的免疫系统。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Shu Kam Mok | 62 | - | Member of Scientific & Medical Advisory Board |
Pasi Antero Janne | - | - | Member of Scientific & Medical Advisory Board |
George Simon | - | - | Member of Scientific & Medical Advisory Board |
John Rodney Varner | 66 | 2012 | Co-Founder, Chairman, President & CEO |
Brent M. Longnecker | 67 | 2020 | Independent Director |
George K. Gittes | - | 2020 | Member of Scientific Advisory Board |
Jose Antonio Moreno Toscano | 50 | 2020 | Independent Director |
Michael Morse | - | 2021 | Member of Clinical Advisory Board |
James E. Rothman | 72 | 2012 | Strategic Advisor to the Board of Directors |
William R. Wilson | 73 | 2020 | Independent Director |
Andrew B. Becker | - | 2021 | Member of Clinical Advisory Board |
George E. Peoples | - | 2021 | Member of Clinical Advisory Board |
Jack A. Roth | - | - | Chairman of Scientific & Medical Advisory Board |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核